345 related articles for article (PubMed ID: 28162024)
21. Treatment of renal cell carcinoma: Current status and future directions.
Barata PC; Rini BI
CA Cancer J Clin; 2017 Nov; 67(6):507-524. PubMed ID: 28961310
[TBL] [Abstract][Full Text] [Related]
22. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
[TBL] [Abstract][Full Text] [Related]
23. Clinical decision-making for immunotherapy in metastatic renal cell carcinoma.
Schmidinger M
Curr Opin Urol; 2018 Jan; 28(1):29-34. PubMed ID: 29045250
[TBL] [Abstract][Full Text] [Related]
24. Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma.
Rini BI; McDermott DF; Hammers H; Bro W; Bukowski RM; Faba B; Faba J; Figlin RA; Hutson T; Jonasch E; Joseph RW; Leibovich BC; Olencki T; Pantuck AJ; Quinn DI; Seery V; Voss MH; Wood CG; Wood LS; Atkins MB
J Immunother Cancer; 2016; 4():81. PubMed ID: 27891227
[TBL] [Abstract][Full Text] [Related]
25. New agents and new targets for renal cell carcinoma.
Philips GK; Atkins MB
Am Soc Clin Oncol Educ Book; 2014; ():e222-7. PubMed ID: 24857106
[TBL] [Abstract][Full Text] [Related]
26. New therapeutic developments in renal cell cancer.
Prenen H; Gil T; Awada A
Crit Rev Oncol Hematol; 2009 Jan; 69(1):56-63. PubMed ID: 18752971
[TBL] [Abstract][Full Text] [Related]
27. Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions.
Lalani AA; McGregor BA; Albiges L; Choueiri TK; Motzer R; Powles T; Wood C; Bex A
Eur Urol; 2019 Jan; 75(1):100-110. PubMed ID: 30327274
[TBL] [Abstract][Full Text] [Related]
28. Immunotherapeutic strategies in kidney cancer--when TKIs are not enough.
Biswas S; Eisen T
Nat Rev Clin Oncol; 2009 Aug; 6(8):478-87. PubMed ID: 19546865
[TBL] [Abstract][Full Text] [Related]
29. Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma.
Carlo MI; Voss MH; Motzer RJ
Nat Rev Urol; 2016 Jul; 13(7):420-31. PubMed ID: 27324121
[TBL] [Abstract][Full Text] [Related]
30. Immunotherapy for renal cell carcinoma.
Rosenblatt J; McDermott DF
Hematol Oncol Clin North Am; 2011 Aug; 25(4):793-812. PubMed ID: 21763968
[TBL] [Abstract][Full Text] [Related]
31. Safety of available treatment options for renal cell carcinoma.
Derosa L; Albiges L; Massard C; Loriot Y; Fizazi K; Escudier B
Expert Opin Drug Saf; 2016 Aug; 15(8):1097-106. PubMed ID: 27142582
[TBL] [Abstract][Full Text] [Related]
32. Importance of Multiparametric Evaluation of Immune-Related T-Cell Markers in Renal-Cell Carcinoma.
Kawashima A; Uemura M; Nonomura N
Clin Genitourin Cancer; 2019 Dec; 17(6):e1147-e1152. PubMed ID: 31473121
[TBL] [Abstract][Full Text] [Related]
33. Recent developments in renal cell cancer immunotherapy.
Wysocki PJ; Zolnierek J; Szczylik C; Mackiewicz A
Expert Opin Biol Ther; 2007 May; 7(5):727-37. PubMed ID: 17477809
[TBL] [Abstract][Full Text] [Related]
34. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy.
Lam JS; Shvarts O; Leppert JT; Figlin RA; Belldegrun AS
J Urol; 2005 Jun; 173(6):1853-62. PubMed ID: 15879764
[TBL] [Abstract][Full Text] [Related]
35. The Current and Evolving Landscape of First-Line Treatments for Advanced Renal Cell Carcinoma.
Calvo E; Porta C; Grünwald V; Escudier B
Oncologist; 2019 Mar; 24(3):338-348. PubMed ID: 30158285
[TBL] [Abstract][Full Text] [Related]
36. The Evaluation of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: Open Challenges in the Clinical Practice.
Raimondi A; Randon G; Sepe P; Claps M; Verzoni E; de Braud F; Procopio G
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31480348
[TBL] [Abstract][Full Text] [Related]
37. Combining Radiotherapy with Immunocheckpoint Inhibitors or CAR-T in Renal Cell Carcinoma.
Santoni M; Heng DYC; Aurilio G; Iozzelli A; Servi L; Fabiani A; Giannini M; Mazzucchelli R; Cimadamore A; Scarpelli M; Zaghloul MS; Battelli N; Montironi R
Curr Drug Targets; 2020; 21(4):416-423. PubMed ID: 31625471
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy for metastatic renal cell carcinoma: is it a therapeutic option yet?
Guida M; Colucci G
Ann Oncol; 2007 Jun; 18 Suppl 6():vi149-52. PubMed ID: 17591810
[TBL] [Abstract][Full Text] [Related]
39. Emerging tyrosine kinase inhibitors for the treatment of renal cancer.
Iacovelli R; Albiges L; Escudier B
Expert Opin Emerg Drugs; 2015 Sep; 20(3):379-92. PubMed ID: 25982181
[TBL] [Abstract][Full Text] [Related]
40. Metastatic clear cell renal cell carcinoma: A review of current therapies and novel immunotherapies.
Thomas JS; Kabbinavar F
Crit Rev Oncol Hematol; 2015 Dec; 96(3):527-33. PubMed ID: 26299335
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]